NEW YORK, March 11, 2026, 12:21 EDT
- PFE slipped roughly 0.4% to $27.05 by midday Wednesday in New York.
- U.S. vaccine advisers have decided not to pursue efforts to scrutinize mRNA COVID vaccines, according to The Washington Post. The current system stands unchanged for now.
- Pfizer’s eczema treatment hit its main target in a mid-stage trial, moving the drug toward a late-stage study later this year. More comprehensive safety results are yet to come.
Pfizer slipped roughly 0.4% to $27.05 midday Wednesday in New York. Investors reacted after the Washington Post said U.S. vaccine advisers scrapped plans to scrutinize mRNA COVID vaccines, removing a potential regulatory obstacle for the company’s vaccine segment.
That’s important for Pfizer, which still faces pressure to deliver fresh products and more consistent policy support for its shares. Just last month, the company stuck to its 2026 revenue target of $59.5 billion to $62.5 billion, with adjusted earnings forecast between $2.80 and $3.00 per share. Pfizer has also indicated it doesn’t see revenue growth coming back until 2029, as COVID demand ebbs and older drugs lose exclusivity.
Monday’s eczema data handed Pfizer an opportunity. Its trispecific antibody, tilrekimig—which targets three inflammatory pathways in one—hit the primary endpoint in a mid-stage trial, clearing the way for Phase 3 later this year. Mike Vincent, head of inflammation and immunology at Pfizer, called the topline Phase 2 results “encouraging.” Pfizer
BMO’s Evan Seigerman pointed out the data hint at a profile that could go toe-to-toe with Regeneron and Sanofi’s Dupixent. Still, he cautioned, the real test will come with more detailed safety results and a closer look at the placebo response.
Pfizer is chasing growth in obesity treatments as sales slip for older drugs. In February, the company outlined plans for over 20 obesity trials kicking off in 2026, setting sights on a first approval in 2028. Chief Executive Albert Bourla signaled confidence—he’s “not worried” about pricing pressure. Still, Gabelli Funds’ Daniel Barasa summed up the recent results as “good, but not category-defining.” Eli Lilly and Novo Nordisk remain the names to beat in this space. Reuters
The bull case isn’t locked in just yet. Pfizer plans to release more in-depth eczema findings down the line, and its Metsera-based obesity drug has already posted a 10% dropout rate tied to side effects in a phase 2 trial—a signal that early buzz doesn’t always mean lasting revenue.
The policy landscape still looks unsettled. According to Wednesday’s report, advisers are sticking with the September 2025 policy that puts COVID vaccine decisions in the hands of patients and their doctors. Pfizer, for its part, is still navigating the same pricing and tariff dynamics that secured it a three-year exemption from looming U.S. pharmaceutical tariffs.
Pfizer’s market cap sits at about $135 billion, with shares hovering close to $27. Investors are eyeing more detailed eczema results next, plus any hints from the CDC’s vaccine meeting next week on whether COVID shot guidelines will stay put.
